Personalized Drug Analysis in B Cell Chronic Lymphocytic Leukemia Patients
نویسندگان
چکیده
منابع مشابه
Personalized Drug Analysis in B Cell Chronic Lymphocytic Leukemia Patients
BACKGROUND B cell chronic lymphocytic leukemia (B-CLL) is the most common adult leukemia in the Western world. Although therapeutic advances have notably improved the outcome for many patients, B-CLL remains an incurable disease. The purpose of this study was to search for therapeutic drugs based on altered pathways in individual patients. MATERIAL AND METHODS Genes from microarray data were ma...
متن کاملAnalysis of HLA-G Gene Expression in B-Lymphocytes from Chronic Lymphocytic Leukemia Patients
The human leukocyte antigen G (HLA-G) molecule exhibits limited tissue distribution, low polymorphism and alternative splicings that generate seven HLA-G isoforms. HLA-G exerts multiple immunoregulatory functions. Recent studies indicate an ectopic up-regulation in tumor cells that may favor their escape from anti-tumor immune responses. This study it is an effort to clarify the presence of HLA...
متن کاملB-cell Chronic Lymphocytic Leukemia
Purpose: To review the recent major advances in the molecular and cell biology of B-cell chronic lymphocytic leukemia (B-CLL). Methods: Weanalyzed thenatureofmalignantB-CLLB cells and their interactions with the microenvironment. Results: B-CLL is a malignancy of a mantle zonebased subpopulation of anergic, self-reactive, activated CD51 B cells devoted to the production of polyreactive natural ...
متن کاملfish analysis for del6q21 and del17p13 in b-cell chronic lymphocytic leukemia in iranians
conclusions it was demonstrated that the presence of del6q21 in b-cll patients indicates poor prognosis and on the contrary, presence of del17p13 points at the good prognostic value of the disease. results deletion of 17p13 was found in 11 (16.6%) and deletion 6q21 was present in 5 (7.5%). statistical analyses were performed to investigate the correlation of these molecular-cytogenetic findings...
متن کاملRituximab therapy of patients with B-cell chronic lymphocytic leukemia.
Rituximab (IDEC-C2B8) is a chimeric antibody that binds to the B-cell surface antigen CD20. Rituximab has significant activity in follicular non-Hodgkin lymphomas. Much less is known about the effects in chronic lymphocytic leukemia (CLL). We have initiated a phase II trial to evaluate the efficacy and safety of rituximab in patients with CD20+ pretreated CLL. To avoid the rituximab-associated ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medical Science Monitor
سال: 2017
ISSN: 1643-3750
DOI: 10.12659/msm.900738